Clinically, PRSS2 is significantly upregulated in various digestive system tumors (e.g., pancreatic, gastric, cholangiocarcinoma, and colorectal cancers) [5–9], as well as in non-digestive system tumors such as breast, prostate, and ovarian cancers [10,11]. Here, PRSS2 is linked to digestive system neoplasm.